Amarin Announces Results from Exploratory Phase 2a Study of EN101 in – Businesswire.com

Amarin Announces Results from Exploratory Phase 2a Study of EN101 in – Businesswire.com
DUBLIN–( BUSINESS WIRE )–Amarin Corporation plc (NASDAQ:AMRN) today announced encouraging top line results from an exploratory Phase 2a multi-centre, dose-ranging, cross-over clinical study of EN101 in patients with myasthenia gravis, a chronic

No related content found.

Speak Your Mind